HANA REPORTS TALOTREXIN DATA

A A

Hana Biosciences has announced the results of Phase I trials in solid tumors and non small cell lung cancer (NSCLC) with Talotrexin (PT-523).

Talotrexin (PT-523) is a novel antifolate drug candidate under development for treatment of various types of tumors. Talotrexin has demonstrated enhanced antitumor activity in a broad spectrum of cancer models by targeting the enzyme DHFR to prevent DNA synthesis in tumor cells and inhibit tumor growth. Preclinical studies suggest that Talotrexin, as compared to methotrexate, the most widely used antifolate, enters into cells up to 10 times more efficiently and demonstrates 10- to 100-fold more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance.